Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.49 |
| ▸ | SLC6A4 known ✓ | P31645 | 12/20 | 0.46 |
| ▸ | SLC6A2 known ✓ | P23975 | 11/20 | 0.46 |
| ▸ | SLC6A3 known ✓ | Q01959 | 4/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL6388246 | 1.00 | HRH1 (0.49) | HRH1GBA1SLC6A4SLC6A2SLC6A3 | |
| Fumaric Acid SCHEMBL7491467 | 0.95 | HRH1 (0.46) | HRH1GBA1SLC6A4SLC6A2SLC6A3 | |
| Fumaric Acid SCHEMBL7491458 | 0.95 | HRH1 (0.46) | HRH1GBA1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6383375 | 0.87 | GBA1 (0.56) | GBA1SLC6A4SLC6A2 | |
| SCHEMBL7544955 | 0.81 | GBA1 (0.50) | GBA1SLC6A4SLC6A2 | |
| SCHEMBL15667971 | 0.77 | HRH4 (0.45) | GBA1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL29889431 | 0.77 | HRH4 (0.45) | GBA1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL7489765 | 0.77 | HRH4 (0.45) | GBA1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL29942450 | 0.75 | ATM (0.53) | SLC6A4 | |
| Fumaric Acid SCHEMBL5997614 | 0.74 | SLC6A2 (0.78) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1598068-A1 | Antipsychotic heterocycle compounds | Bristol-Myers Squibb Company (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1242072-A4 | ANTIPSYCHOTIC HETEROCYCLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6476051-B2 | FOR THERAPY OF PSYCHOSIS, ACUTE MANIA, MILD ANXIETY STATES, OR DEPRESSION IN COMBINATION WITH PSYCHOTIC EPISODES | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-05 | — | — | US | disclosed |
| EP-1242072-A1 | ANTIPSYCHOTIC HETEROCYCLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020072611-A1 | Antipsychotic heterocycle compounds | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-13 | — | — | US | disclosed |
| EP-1146871-A4 | ANTIDEPRESSANT HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2002-04-17 | — | — | EP | disclosed |
| EP-1146871-A1 | ANTIDEPRESSANT HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2001043740-A1 | ANTIPSYCHOTIC HETEROCYCLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
| US-6225324-B1 | POTENT INHIBITION OF 5-HT REUPTAKE; 1,3-DISUBSTITUTED PYRROLIDINE, 1,4-DISUBSTITUTED PIPERIDINE, OR 1,4-DISUBSTITUTED HEXAHYDROAZEPINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2001-05-01 | — | — | US | disclosed |
| WO-2000044376-A1 | ANTIDEPRESSANT HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072611-A1 | Antipsychotic heterocycle compounds | HTR2C, DRD2, HTR1A | HRH1 176/4885SLC6A4 60/4885SLC6A2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.